{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-013557","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2022-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.560521+00:00","generated_at":"2026-06-23T23:40:39.432231+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Protalix Q2 net loss narrows to $5.3M; PRX-102 Phase III CSR complete","bullets":["Total revenues $8.8M ($3.4M product sales +$5.4M license/R&D), up 38% YoY.","Net loss $5.3M ($0.11/share) vs. $11.2M ($0.25/share) in Q2 2021.","Cash and equivalents $28.6M at June 30, 2022.","Phase III BALANCE trial CSR confirms positive topline results for PRX-102 in Fabry disease.","Appointed Shmuel Ben Zvi, Ph.D. to Board as Audit Committee Chairman."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-013557","json":"https://secwatch.observer/filing/0001558370-22-013557.json","markdown":"https://secwatch.observer/filing/0001558370-22-013557.md","text":"https://secwatch.observer/filing/0001558370-22-013557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837022013557/0001558370-22-013557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837022013557/plx-20220815x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T23:40:39.432231+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}